Prior research has established that in BCa, H3K18la promotes tumor proliferation and migration by up-regulating LCN2 expression, and facilitates cisplatin resistance by enhancing the expression of YBX1 and YY1 [11,14]. This evidence concerns the gene LCN2 and neoplasm.